Emkay Global Financial's research report on Bajaj Finserv
Our positive stance on the stock is underpinned by three factors: 1) Notwithstanding temporary hiccups, the established businesses of BAF and BAGIC remain arguably the best in the industry and maintain an edge. 2) BALIC has navigated well through challenging times and is now among the top nonbank-owned franchises. 3) Newer businesses like Bajaj Finserv AMC and Bajaj Securities complete the product suite, while Bajaj Finserv Health provides a huge optionality in the long term with its endeavor to create India's ‘Optum’ in the healthcare space. Overall, we see BJFIN’s consolidated PAT compounding at 24% over FY24-27E to Rs154bn. We believe the BJFIN play is apt for gaining exposure to established and fortified franchises like BAF and BAGIC, along with optionality emerging from newer ventures like Bajaj Finserv Health.
Outlook
We initiate coverage on Bajaj Finserv (BJFIN) with a BUY recommendation and Sep-25E TP of Rs2,150/share (~16% upside), implying FY26E consolidated P/B of 4.1x.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.